Prolia (Denosumab) vs Evenity (Romosozumab): Cost and Access Head-to-Head

How Each Drug Works: Different Targets, Different Goals

Denosumab and romosozumab both strengthen bone, but they do so at opposite ends of bone biology. Denosumab blocks RANK ligand, the protein that activates osteoclasts (bone-destroying cells), so bone resorption slows. Romosozumab neutralizes sclerostin, a protein made by osteocytes that normally suppresses bone formation, so it simultaneously accelerates bone building and modestly reduces resorption.

Denosumab: Pure Antiresorptive Action

By silencing RANK ligand, denosumab prevents osteoclast maturation and survival. Bone mineral density (BMD) gains at the lumbar spine average 9.2% at 3 years compared with baseline, with gains continuing beyond 10 years in open-label extension data. Because RANK ligand is also expressed in immune tissue, denosumab carries a real risk of serious infections; the prescribing label lists cellulitis and opportunistic infections as documented adverse events.

Discontinuation requires a plan. Stopping denosumab abruptly can trigger rebound resorption and rapid bone loss, sometimes exceeding the BMD gained during treatment. Transitioning to a bisphosphonate before stopping is the standard recommended strategy per the American Society for Bone and Mineral Research (ASBMR).

Romosozumab: Dual Mechanism in a Fixed Window

Romosozumab's dual action produces faster BMD accrual than most antiresorptive agents. In the phase 3 FRAME trial (N=7,180), one year of romosozumab followed by denosumab produced a 75% reduction in new vertebral fractures at 24 months compared with placebo followed by denosumab. The treatment window is fixed: the FDA approved romosozumab for exactly 12 monthly doses because the anabolic effect diminishes after that period, and because extending exposure adds cardiovascular risk without additional bone benefit.

After the 12-month course ends, patients must transition to an antiresorptive agent (typically denosumab or a bisphosphonate) to preserve the gains. Skipping that transition leads to rapid reversal of the BMD increase.

Fracture Efficacy: Reading the Trial Data Carefully

The two headline trials are not directly comparable because they used different control groups, different patient populations, and different follow-up periods. Treating the numbers as equivalent is a clinical error.

FREEDOM Trial (Denosumab vs Placebo)

The FREEDOM trial (N=7,808) enrolled postmenopausal women with a T-score between -2.5 and -4.0 at the lumbar spine or total hip. Over 36 months, denosumab 60 mg every 6 months reduced new vertebral fractures by 68% (7.2% placebo vs. 2.3% denosumab, P<0.001), hip fractures by 40%, and nonvertebral fractures by 20%. The FREEDOM extension, running to 10 years, showed continued BMD gains without a plateau.

ARCH Trial (Romosozumab vs Alendronate)

The ARCH trial (N=4,093) compared 12 months of romosozumab followed by alendronate against alendronate alone in postmenopausal women with osteoporosis and a prior vertebral fracture or a T-score <-2.5 with other risk factors. At 24 months, the romosozumab-to-alendronate sequence reduced new vertebral fractures by 48% vs. Alendronate alone (6.2% vs. 11.9%, P<0.001) and cut clinical fractures by 27%.

Critically, ARCH also found a higher rate of serious cardiovascular events in the romosozumab arm (2.5% vs. 1.9%), which drove the eventual black-box warning. Patients with a myocardial infarction or stroke within the preceding year were excluded from the indication.

Side-by-Side Efficacy Summary

| Outcome | Denosumab (FREEDOM) | Romosozumab (ARCH sequence) | |---|---|---| | New vertebral fracture reduction | 68% vs. Placebo | 48% vs. Alendronate | | Hip fracture reduction | 40% vs. Placebo | 38% vs. Alendronate | | Nonvertebral fracture reduction | 20% vs. Placebo | 19% vs. Alendronate | | Control group | Placebo | Active comparator (alendronate) | | Follow-up | 36 months | 24 months (12-month romosozumab + 12-month alendronate) |

The larger percentage for denosumab partly reflects the weaker placebo comparator rather than superior absolute efficacy. Alendronate itself reduces vertebral fractures by roughly 45-50% vs. Placebo, so the 48% reduction over alendronate in ARCH translates to a much larger benefit over no treatment.

Safety Profiles: Where the Real Differences Live

Denosumab Safety

• Hypocalcemia (black-box warning): Baseline calcium and vitamin D correction is mandatory before every dose. Patients with eGFR <30 mL/min are at highest risk.
• Osteonecrosis of the jaw (ONJ): Rare but documented; estimated incidence 0.04% per patient-year in osteoporosis dosing.
• Atypical femur fractures: Risk increases with duration beyond 5 years, similar to bisphosphonates.
• Serious infections: Cellulitis, endocarditis, and opportunistic infections have been reported.
• Rebound vertebral fractures: Multiple vertebral fractures within 18 months of stopping are reported in case series; the ASBMR task force published explicit discontinuation guidance in 2019.

Romosozumab Safety

• Cardiovascular events (black-box warning): In ARCH, the absolute risk difference for MACE (major adverse cardiovascular events) was approximately 0.6 percentage points over 12 months. Romosozumab is contraindicated in patients with MI or stroke within the prior year.
• Hypocalcemia: Present but generally less severe than with denosumab.
• ONJ and atypical femur fracture: Reported at low rates consistent with other bone agents.
• Injection site reactions: More common than with denosumab due to the larger monthly injection volume (two separate 1.17 mL injections per visit).

For a postmenopausal woman with prior cardiovascular disease, denosumab is the safer choice by labeling. For a patient with severe hypocalcemia risk or advanced CKD, romosozumab's cardiovascular warning may be less relevant than denosumab's hypocalcemia risk, depending on the clinical picture.

Cost Comparison: List Price, Insurance, and Out-of-Pocket Reality

Cost is frequently the deciding factor in practice. The gap between denosumab and romosozumab is substantial.

Wholesale Acquisition Cost (WAC)

Denosumab (Prolia) carries a 2025 WAC of approximately $1,390 per 60 mg prefilled syringe, yielding roughly $2,780 per year for two doses. Romosozumab (Evenity) lists at approximately $2,100 per monthly 210 mg dose (two 105 mg syringes), totaling roughly $25,200 for the full 12-month course. Actual insurer-negotiated prices are lower, but the ratio stays broadly similar: romosozumab's course costs about 7-9 times more than one year of denosumab at WAC.

Biosimilar denosumab entered the US market in mid-2024 under the names Jubbonti (Sandoz) and Wyost (Sandoz), with additional biosimilars from Cipla and others pending. Early pricing suggests 15-35% discounts off Prolia's WAC. Romosozumab has no biosimilar competition; its composition-of-matter patent does not expire until 2032.

Medicare Part B Coverage

Both drugs are administered by injection in a clinical setting, qualifying for Medicare Part B reimbursement rather than Part D. Part B covers 80% of the Medicare-approved amount after the patient meets the Part B deductible ($257 in 2025). Because romosozumab requires monthly office visits for 12 months, the administration fees also add to patient cost-sharing.

Commercial Insurance Prior Authorization

Most commercial plans cover both agents but apply step-therapy for romosozumab. A typical prior-authorization requirement for Evenity includes:

1. Documented T-score <-2.5 at lumbar spine, femoral neck, or total hip, or a prior osteoporotic fracture.
2. Failure of, intolerance to, or contraindication to at least one bisphosphonate (usually 12 months of oral alendronate).
3. No myocardial infarction or stroke within the preceding 12 months.
4. Documented adequate calcium and vitamin D status.

Denosumab's prior-auth bar is generally lower: a T-score <-2.5 or a documented fragility fracture typically suffices, without a bisphosphonate-failure requirement on most major plans.

Patient Assistance Programs

Amgen offers the Prolia One Source program for uninsured or underinsured patients, providing free drug for patients below income thresholds. For Evenity, Amgen's EVENITY FIRST program provides co-pay assistance for commercially insured patients, potentially reducing monthly out-of-pocket cost to $0 for eligible individuals. Neither program covers Medicare patients by law. Patients on Medicare with high cost-sharing should explore the Medicare Extra Help program and State Pharmaceutical Assistance Programs (SPAPs).

Choosing Between Them: A Clinical Decision Framework

The following framework integrates FDA labeling, ARCH and FREEDOM data, ASBMR guidelines, and the 2022 Endocrine Society clinical practice guideline for postmenopausal osteoporosis into a practical decision tree. It is a proposed framework for physician review, not a substitute for individualized clinical judgment.

Step 1: Screen for romosozumab contraindications first. Any MI or stroke within the prior 12 months, or high cardiovascular risk without clear fracture emergency, steers the choice toward denosumab. This is a hard stop per FDA labeling.

Step 2: Assess fracture urgency. For patients with a very high fracture risk, defined by the 2022 Endocrine Society guideline as a prior hip or vertebral fracture plus T-score <-2.5, or multiple prior fractures, romosozumab's faster anabolic bone accrual offers a clinically meaningful benefit over starting with denosumab alone, assuming no cardiovascular contraindication.

Step 3: Evaluate prior therapy. A patient transitioning off long-term bisphosphonate therapy already has baseline antiresorptive coverage. Romosozumab's anabolic effect still operates on top of that background, and ARCH enrolled such patients. Denosumab is a reasonable continuation after bisphosphonate therapy but adds no anabolic stimulus.

Step 4: Consider CKD and calcium status. Denosumab can be used in moderate-to-severe CKD with close monitoring, though hypocalcemia risk rises sharply below eGFR 30. The FDA label for Prolia recommends more frequent calcium monitoring in stage 4-5 CKD. Romosozumab's safety data in severe CKD are limited; it is generally avoided in eGFR <30.

Step 5: Weigh cost and access. For patients without insurance or facing high cost-sharing, denosumab (and now biosimilar denosumab) is far more accessible. Romosozumab's patient assistance program can eliminate cost-sharing for commercially insured patients, but the monthly office visit requirement remains a burden.

Step 6: Plan the exit strategy before you start. Both drugs require a transition plan. For romosozumab, the 12-month course must be followed by an antiresorptive (typically denosumab or zoledronic acid). For denosumab used long-term, discontinuation must include a bridge to bisphosphonate therapy per ASBMR recommendations.

Administration: Practical Differences for Patients and Clinicians

Injection Schedule and Setting

Denosumab is one 1 mL subcutaneous injection every 6 months. It can be self-administered at home in some practice settings, though most US clinicians administer it in-office to ensure compliance. Romosozumab requires two separate 1.17 mL subcutaneous injections given consecutively once per month, always administered by a healthcare provider. The frequency and dual-injection requirement make monthly office visits effectively mandatory.

Monitoring Requirements

Both drugs require baseline serum calcium and 25-hydroxyvitamin D before starting. Denosumab patients should supplement with at least 1,000 mg elemental calcium and 800 IU vitamin D daily; those with malabsorption or advanced CKD may need higher doses. The Endocrine Society guideline recommends BMD monitoring by DXA every 1-2 years during active treatment. Romosozumab patients warrant a baseline ECG or cardiology clearance if borderline cardiovascular risk is present, though this is not mandated by labeling.

Biosimilars and the Competitive Field Through 2026

The biosimilar entry for denosumab reshapes the cost argument substantially. Jubbonti and Wyost, both Sandoz products approved by the FDA in June 2024, are interchangeable biosimilars, meaning pharmacists can substitute them for Prolia without a new physician prescription in states that permit interchangeable substitution. Interchangeable biosimilar status is significant: it accelerates market adoption and price competition in a way that non-interchangeable biosimilars typically do not.

Romosozumab faces no such competition. Amgen holds composition-of-matter and formulation patents through at least 2032. Pricing pressure on romosozumab will not come from biosimilar entry before that window; it will come only from payer negotiation and rebate agreements.

The practical consequence: for a payer or patient choosing between drugs in 2025 and beyond, the denosumab cost trajectory is downward while romosozumab's cost trajectory is flat or slightly upward with inflation adjustments.

What Guidelines Say

The 2022 Endocrine Society clinical practice guideline on postmenopausal osteoporosis recommends romosozumab as a first-line option for patients at "very high fracture risk," stating: "For postmenopausal women at very high risk of fracture, we suggest initiating treatment with an anabolic agent (teriparatide, abaloparatide, or romosozumab) rather than an antiresorptive agent." Denosumab is listed as an alternative first-line option for patients at high risk who are not candidates for anabolic therapy or who have specific indications such as breast cancer-related bone loss or kidney disease.

The ASBMR 2022 task force report on atypical femur fractures and bisphosphonate holiday reinforces that patients on long-term denosumab who stop abruptly are at risk for rebound vertebral fractures, a risk not present with romosozumab's fixed-course design.

Real-World Access: Geographic and Practice-Setting Gaps

Patients in rural areas or those without reliable monthly transportation face a structural barrier to romosozumab. Twelve monthly in-office injections over one year is a meaningful commitment. Denosumab's twice-yearly schedule is more forgiving for patients with limited access to outpatient infusion or injection centers.

Telehealth prescribing of injectable osteoporosis medications is also constrained: both drugs require in-person administration, and the monitoring requirements (calcium checks, DXA scans) need local radiology and lab access. For patients relying primarily on telehealth, the prescribing conversation is possible remotely, but drug delivery still requires a local provider relationship.

Key Takeaways Before Talking to Your Clinician

Denosumab (Prolia) suits patients who need a well-established, lower-cost, twice-yearly injection and who may have CKD, prior bisphosphonate use, or a lower cardiovascular risk profile. The biosimilar availability in 2024 improves affordability further.

Romosozumab (Evenity) is the stronger option for patients with very high fracture urgency and no recent cardiovascular events, particularly those who have already tried bisphosphonates. The higher cost is partially offset by patient assistance programs for commercially insured patients, and the fixed 12-month course removes the long-term discontinuation complexity that denosumab carries.

Ask your clinician specifically about your 10-year FRAX score, your most recent DXA T-scores, your cardiovascular history, and your kidney function. Those four data points define which drug makes clinical sense for you.